Trial
NCT03744247
Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Sun Yat-sen University
Collaborators
First Affiliated Hospital, Sun Yat-Sen University; Kaiping Central Hospital; Guangzhou No.12 People's Hospital; The First Affiliated Hospital of University of South China
Condition
Hepatocellular Carcinoma
Intervention
Lenvatinib
Why stopped
No paritcipants enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-02